CCEL
Cryo-Cell International, Inc.
CCEL lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CCEL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Weak |
CCEL's revenue and cash flow are currently stable, but its profitability and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CCEL PE Valuation
CCEL has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 68x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CCEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Decline | |
| -- | |
| Limited | |
| -- |
Analysts expect CCEL to return to profit, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CCEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.08 | — |
| Q3 2026 | -$0.22 | -$0.15 |
| Q2 2026 | -$0.29 | -$0.26 |
| Q1 2026 | -$0.32 | -3300% |
| Q4 2025 | -$0.30 | -700% |
| Q3 2025 | -$0.07 | +$0.99 |
| Q2 2025 | -$0.03 | +$1.08 |
| Q1 2025 | $0.01 | +$1.17 |
| Q4 2024 | $0.05 | +$1.19 |
CCEL is still losing money, but far less than before: $0.22 per share over the past year, against $1.16 at its worst in early 2024.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CCEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8M | 0% |
| Q2 2026 | $7.8M | -1.9% |
| Q1 2026 | $7.7M | -3.6% |
| Q4 2025 | $7.8M | -2.3% |
| Q3 2025 | $7.8M | -3% |
| Q2 2025 | $7.9M | -1.4% |
| Q1 2025 | $8M | +1.5% |
| Q4 2024 | $8M | +1.9% |
CCEL's revenue has held roughly level: $8M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +3.8 points |
| Q2 2026 | 15% | -3.4 points |
| Q1 2026 | 10% | -3.3 points |
| Q4 2025 | -51% | -49 points |
| Q3 2025 | 24% | +7.1 points |
| Q2 2025 | 19% | +1.5 points |
| Q1 2025 | 13% | +2.8 points |
| Q4 2024 | -1.5% | +204 points |
CCEL has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CCEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CCEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1M | -58% |
| Q2 2026 | $1.8M | +181% |
| Q1 2026 | $584.8K | -34% |
| Q4 2025 | $1.2M | -44% |
| Q3 2025 | $2.5M | +11% |
| Q2 2025 | $644.6K | +2891% |
| Q1 2025 | $892K | +$1.7M |
| Q4 2024 | $2.1M | +32% |
CCEL still generates free cash flow, though less than at its 2020 peak: $5M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CCEL on cash flow, with more consistent year-over-year improvement.
CCEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +9.7K shares |
| 1 year | -0.1% | -8.5K shares |
| 3 years | -3.3% | -277K shares |
| 5 years | -7.2% | -627K shares |
| Available history | -4.1% | -347K shares |
CCEL has 8M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $80,883 |
| Q2 2025 | $88,619 |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16,400 |
| Q2 2024 | $1.2M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CCEL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CCEL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.5x | High |
| Q2 2026 | 10.3x | High |
| Q1 2026 | 7.7x | High |
| Q4 2025 | 6.0x | High |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.8x | Healthy |
| Q4 2024 | 2.0x | Healthy |
CCEL's net debt is about 6.5 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CCEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.8 | Neutral |
| Stochastic | 88.0 | Overbought |
CCEL's weekly RSI is 67 (neutral) and its Stochastic is 88 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CCEL PE vs Healthcare Sector
| Metric | CCEL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CCEL has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CCEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.62 | 17% above |
| 20 week MA | $4.16 | 30% above |
| 50 week MA | $3.75 | 44% above |
| 100 week MA | $4.69 | 15% above |
| 200 week MA | $5.37 | 0.6% above |
CCEL has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CCEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.22 | $7.50 | +3.9% |
| 2021 | $7.50 | $12.4 | +65% |
| 2022 | $12.4 | $4.30 | -65% |
| 2023 | $4.30 | $5.75 | +34% |
| 2024 | $5.75 | $7.72 | +34% |
| 2025 | $7.72 | $3.50 | -55% |
| 2026 YTD | $3.50 | $5.40 | +54% |
CCEL has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.